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Abstract. 
 
Cell migration is modulated by regulatory 
molecules such as growth factors, oncogenes, and the 
tumor suppressor PTEN. We previously described inhi-
bition of cell migration by PTEN and restoration of 
motility by focal adhesion kinase (FAK) and p130 Crk-
associated substrate (p130
 
Cas
 
). We now report a novel 
pathway regulating random cell motility involving Shc 
and mitogen-activated protein (MAP) kinase, which is 
downmodulated by PTEN and additive to a FAK path-
way regulating directional migration. Overexpression 
of Shc or constitutively activated MEK1 in PTEN-
reconstituted U87-MG cells stimulated integrin-
mediated MAP kinase activation and cell migration. 
Conversely, overexpression of dominant negative Shc 
inhibited cell migration; Akt appeared uninvolved. 
PTEN directly dephosphorylated Shc. The migration 
induced by FAK or p130
 
Cas
 
 was directionally persistent 
and involved extensive organization of actin microﬁla-
ments and focal adhesions. In contrast, Shc or MEK1 
induced a random type of motility associated with less 
actin cytoskeletal and focal adhesion organization. 
These results identify two distinct, additive pathways 
regulating cell migration that are downregulated by tu-
mor suppressor PTEN: one involves Shc, a MAP kinase 
pathway, and random migration, whereas the other in-
volves FAK, p130
 
Cas
 
, more extensive actin cytoskeletal 
organization, focal contacts, and directionally persistent 
cell motility. Integration of these pathways provides an 
intracellular mechanism for regulating the speed and 
the directionality of cell migration.
Key words: Shc • focal adhesion kinase • integrin • 
cell migration • PTEN
 
C
 
ELL
 
 migration is important for embryonic develop-
ment, wound repair, inflammation, and cancer in-
vasion. Although an extensive literature has impli-
cated a variety of molecules in cell motility, relatively little
is known about how the process of cell migration is inte-
grated intracellularly to control the directionality and the
speed of migration. Cell motility can be regulated or mod-
ulated by growth factors and cytokines, small G proteins,
oncogenes, and the newly discovered tumor suppressor
protein PTEN (Hynes and Lander, 1992; Stossel, 1993; Ol-
iver et al., 1994; Huttenlocher et al., 1995; Nobes and Hall,
1995; Lauffenburger and Horwitz, 1996; Sheetz et al.,
1998; Tamura et al., 1998, 1999a). PTEN is a tumor sup-
pressor gene mutated in a wide variety of human can-
cers, including breast, prostate, and brain cancer (Li and
Sun, 1997; Li et al., 1997; Steck et al., 1997). PTEN expres-
sion can suppress migration, invasion, tumorigenicity, and
growth of human tumor cells (Furnari et al., 1997; Cheney
et al., 1998; Li and Sun, 1998; Tamura et al., 1998; Whang
et al., 1998).
PTEN encodes a protein tyrosine phosphatase motif.
Substrates of PTEN identified to date, both in vitro and in
living cells, include the lipid phosphatidylinositol 3,4,5-tris-
phosphate (PIP
 
3
 
)
 
1
 
 (Maehama and Dixon, 1998; Stambolic
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1. 
 
Abbreviations used in this paper: 
 
Csk, COOH-terminal Src kinase;
ERK, extracellular signal-related kinase; FAK, focal adhesion kinase;
FRNK, dominant negative FAK truncation; GFP, green fluorescent pro-
tein; HA, hemagglutinin; MAP, mitogen-activated protein; MEK, MAP
or ERK kinase; p130
 
Cas
 
, p130 Crk-associated substrate; PIP
 
3
 
, phosphati-
dylinositol 3,4,5-trisphosphate. 
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et al., 1998) and the phosphoprotein focal adhesion kinase
(FAK) (Tamura et al., 1998). Purified PTEN can remove a
specific phosphate group from PIP
 
3
 
, thereby inhibiting
protein kinase B (also known as Akt), which in turn partic-
ipates in cell growth control and inhibits the apoptosis
pathway. Recent experiments using PTEN knockout mice
and tumor cell lines indicate that PTEN is essential for
embryonic development and sensitivity to apoptotic stim-
uli; the latter process has been linked to the lipid phos-
phatase activity of PTEN (Davies et al., 1998; Di Cristo-
fano et al., 1998; Haas-Kogan et al., 1998; Li et al., 1998;
Myers et al., 1998; Stambolic et al., 1998; Suzuki et al.,
1998; Wu et al., 1998).
Because PTEN also has an NH
 
2
 
-terminal domain with
extensive homology to tensin, a protein that interacts with
actin filaments at focal adhesions, we have focused on ana-
lyzing roles of PTEN in integrin-mediated cell migration
and signal transduction. We previously found that the
G129E mutant of PTEN, which lacks lipid phosphatase ac-
tivity but has protein phosphatase activity, can still inhibit
integrin-mediated cell migration, spreading, focal adhe-
sions, and tumor cell invasion, whereas a phosphatase-
dead mutant (C124A) of PTEN cannot (Tamura et al.,
1998, 1999a), demonstrating an important role of protein
phosphatase activity for PTEN function. PTEN directly
associates with FAK and can reduce its tyrosine phosphor-
ylation as well as that of a potential downstream effector,
p130 Crk-associated substrate (p130
 
Cas
 
). Furthermore,
overexpression of FAK or p130
 
Cas
 
 can antagonize the ef-
fects of PTEN on cell migration and invasion (Tamura et al.,
1999a).
We also observed that PTEN inhibits integrin- and
growth factor–mediated mitogen-activated protein (MAP)
kinase signaling pathways. MAP kinase activation could
partially antagonize PTEN function with partial rescue of
cell spreading on fibronectin impaired by PTEN. This inhi-
bition of PTEN was associated with effects on Shc phos-
phorylation (Gu et al., 1998). Shc is an SH
 
2
 
-phosphoty-
rosine–binding adapter protein that links tyrosine kinases
to Ras signaling by recruiting the Grb2-Sos complex to the
plasma membrane in a tyrosine phosphorylation–depen-
dent manner (Rozakis-Adcock et al., 1992; Pronk et al.,
1994; Pawson and Scott, 1997; Wary et al., 1998). PTEN
can inhibit tyrosine phosphorylation of both FAK and Shc.
Both proteins are implicated in integrin signaling and ei-
ther one can bind Grb2 and potentially activate the Ras–
MAP kinase pathway (Schlaepfer et al., 1994; Wary et al.,
1996, 1998; Lin et al., 1997; Schlaepfer and Hunter, 1997;
Gu et al., 1998; Schlaepfer et al., 1998; Tamura et al.,
1998). FAK can also promote integrin-mediated cell mi-
gration through the activation of p130
 
Cas 
 
(Cary et al., 1998;
Sieg et al., 1998). A general role for Shc in activation of
the Ras–MAP kinase pathway is well established. Shc has
been reported to be activated by only certain integrins and
to regulate cell cycle progression in response to specific
extracellular matrix proteins (Wary et al., 1996; Mainiero
et al., 1997). Because the functions of Shc, FAK, and
PTEN appear intertwined, we explored potential addi-
tional cell biological functions for Shc in regulating cell mi-
gration and the cytoskeleton.
In the present study, we examined the regulation of
rates of cell motility versus directionality by the integrated
 
effects of PTEN, Shc, and FAK. We tested for roles of Shc
in cell migration and compared its effects and mechanisms
with those of FAK. Shc was found to regulate integrin-
mediated cell motility. Furthermore, Shc and constitutively
activated MEK1 stimulated random cell migration. In con-
trast, FAK and p130
 
Cas
 
 activated directional (persistent)
cell migration in PTEN-reconstituted cells. These differ-
ences in types of migration patterns correlated with differ-
ences in the extent and organization of actin cytoskeleton.
These findings indicate for the first time that a Shc path-
way can selectively regulate integrin-mediated random
cell motility and that PTEN can suppress cell motility by
distinct pathways that diverge at the level of Shc and FAK.
Integration of these three countervailing regulatory sys-
tems provides an intracellular mechanism for regulating
the speed and the directionality of cell migration.
 
Materials and Methods
 
Expression Plasmids
 
Green fluorescent protein (GFP) expression plasmids based on
pGZ21
 
d
 
xZ that contained no insert, full-length wild-type PTEN, or hem-
agglutinin (HA)-tagged FAK were constructed as described (Tamura et al.,
1998). The dominant negative truncation sequence of FAK (FRNK)
was PCR amplified from HA-FAK using the following forward and re-
verse primers: 5
 
9
 
-AGATCTAGATCTCGGATGAGGATGGAATCCA-
GAAG-3
 
9
 
 and 5
 
9
 
-GCGGCCGCTCAGTGTGGCCGTGTCTGCCCTA-
GCATTTT-3
 
9
 
. The PCR products were digested with BamHI and XbaI
and cloned into pGZ21
 
d
 
xZ. Vesicular stomatis virus epitope–tagged
FRNK was constructed by inserting the vesicular stomatis virus epitope at
the 5
 
9
 
 end of FRNK and the full sequence was verified by DNA sequenc-
ing. The point mutations D92A and C124A were introduced into PTEN
by site-directed mutagenesis as described (Tamura et al., 1998). pSSRa-
Cas-Flag and pSSRa-
 
D
 
SD-Cas-Flag were constructed by inserting the
epitope tag Flag (Eastman Kodak Co.) at the 3
 
9
 
 end of the p130
 
Cas
 
 and
 
D
 
SD-p130
 
Cas
 
 (dominant negative p130
 
Cas
 
) coding sequence in the expres-
sion vectors pSSRa-Cas and pSSRa-
 
D
 
SD-Cas, which were provided by
Dr. Hisamaru Hirai (University of Tokyo, Tokyo, Japan) (Nakamoto et
al., 1997). The plasmid 
 
D
 
SD-p130
 
Cas
 
 functions as a dominant interfering
(dominant negative) inhibitor of p130
 
Cas
 
 because it lacks the substrate do-
main, which contains 15 potential tyrosine phosphorylation sites for bind-
ing of molecules such as Crk and other proteins (Nakamoto et al., 1997).
A pcDNA/Flag-Shc construct was generated by inserting the epitope
tag Flag at the 5
 
9
 
 end of the p52 Shc coding sequence in the expression
vector pcDNA3.1(
 
1
 
). The L-p66-SN Shc cDNA that was used as a tem-
plate for PCR was provided by Drs. E. Migliaccio and P.G. Pelicci (Euro-
pean Institute of Oncology, Milan, Italy). The point mutations Y239F or
Y317F were introduced into the 52-kD isoform of Shc by site-directed mu-
tagenesis or both were introduced to produce the double point mutant
Y239/317F. Mutation of these two tyrosine phosphorylation sites gener-
ates a dominant negative inhibitor of Shc signaling that is initiated by inte-
grins and growth factors (Wary et al., 1998). A plasmid containing
pMCL
 
Å
 
HA-tagged MEK1 (constitutively activated form) was provided
by Dr. N.G. Ahn (Department of Chemistry and Biochemistry, University
of Colorado) (Mansour et al., 1994). The puromycin resistance plasmid
pHA262pur was provided by Dr. Hein te Riele (Netherlands Cancer Insti-
tute, Amsterdam, The Netherlands) (Lacalle et al., 1989). Wild-type Akt
and dominant inhibitory Akt (Akt-K179A) in the pCIS2 expression vec-
tor were provided by Dr. Michael J. Quon (Hypertension-Endocrine
Branch, National Institute of Diabetes and Digestive and Kidney Diseases,
NIH) (Cong et al., 1997). COOH-terminal Src kinase (Csk) in the
pME18SNeo expression vector was provided by Dr. Masato Okada (Institute
for Protein Research, Osaka University, Osaka, Japan) (Nada et al., 1991).
 
Reagents and Antibodies
 
The mAb 2A7 (Upstate Biotechnology Inc.) directed against FAK was
used for immunoprecipitation and a second mAb against FAK (Transduc-
tion Laboratories) was used for immunoblotting. Monoclonal anti-Shc as 
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well as polyclonal anti-p44/42 MAP kinase antibodies were purchased
from Santa Cruz Biotechnology. mAbs for p130
 
Cas
 
, paxillin, Csk, and
phosphotyrosine (RC20) were obtained from Transduction Laboratories.
Monoclonal anti–phospho-p44/42 MAP kinase antibody was from New
England Biolabs, Inc. mAb against Flag (M2) was from Eastman Kodak
Co., mAb against HA was purchased from BAbCO, and mAb against
GFP was from CLONTECH Laboratories. Cy3-conjugated goat antibody
to mouse immunoglobulin G (Jackson ImmunoResearch Laboratories,
Inc.) was used at 1:500 dilution. Rhodamine-labeled phalloidin was from
Molecular Probes. Culture medium and FBS were obtained from GIBCO
BRL and Life Technologies, Inc.
 
Cell Culture, Transfection, and Selection
 
The PTEN-mutated glioblastoma cell line U-87MG was obtained from
American Type Culture Collection. Cells were maintained in DME sup-
plemented with 10% FBS, 100 U/ml penicillin, and 100 
 
m
 
g/ml streptomy-
cin and cultured in 10% CO
 
2
 
 at 37
 
8
 
C. Transfections were performed by
electroporation (LaFlamme et al., 1994). In brief, pGZ21
 
d
 
xZ (10 
 
m
 
g;
cotransfection with 10 
 
m
 
g Flag-Shc, 10 
 
m
 
g HA-FAK, 10 
 
m
 
g Flag-Cas, or
3 
 
m
 
g constitutively activated HA-MEK1) containing either no insert or
PTEN was transfected into 1.5 
 
3
 
 10
 
6
 
 U-87MG cells by electroporation to-
gether with 3 
 
m
 
g pHA262pur. For cotransfections with FRNK or domi-
nant negative Cas or Csk, we used 10 
 
m
 
g of each plasmid in this study. To
increase the expression of transfected genes, 5 mM sodium butyrate was
included in culture media. Cells were subcultured at a 1:3 dilution 24 h af-
ter transfection and were maintained for 2 d in 1 
 
m
 
g/ml puromycin-con-
taining medium. The cells were cultured overnight in the absence of puro-
mycin before use. This selection for transient transfectants resulted in
 
z
 
90% positive cells expressing GFP or GFP-PTEN as determined by flu-
orescence microscopy. For coimmunoprecipitation experiments, U-87MG
cells were cotransfected with GFP tag only, or GFP-tagged wild-type
PTEN, trapping mutant D92A, or inactive phosphatase mutant C124A
(20 
 
m
 
g each) with pHA262pur, and then selected with puromycin as de-
scribed above.
 
Immunoprecipitation and Western Blotting
 
Puromycin-selected U-87MG cells expressing the various constructs were
detached by treating with 0.05% trypsin-EDTA, and then washed with
medium without FBS. 3 
 
3
 
 10
 
5
 
 cells were allowed to spread for the times
indicated on 10-cm plastic tissue culture dishes coated with 10 
 
m
 
g/ml fi-
bronectin. The cells were washed with ice-cold PBS and solubilized in 1%
Triton X-100 lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 2.5 mM sodium pyrophosphate, 1 mM 
 
b
 
-glycero-
phosphate, 1 mM sodium vanadate, 10 
 
m
 
g/ml leupeptin, 10 
 
m
 
g/ml aproti-
nin, 1 mM PMSF) for analysis of protein tyrosine phosphorylation.
For MAP kinase assays, puromycin-selected cells were serum-
restricted overnight in media containing 0.2% FBS. The cells were
washed with PBS and detached by treating with 0.05% trypsin-EDTA.
Trypsin was inactivated with 1 mg/ml soybean trypsin inhibitor. The sus-
pended cells were washed two times in DME with 1% BSA. Cell suspen-
sions were incubated in the same medium at 37
 
8
 
C for 30 min on a rotator.
Thereafter, cells were counted and allowed to spread for 10 min on fi-
bronectin-coated dishes, and then solubilized as described above.
For coimmunoprecipitation experiments, cells were stimulated with
EGF for 5 min, and then solubilized in modified CSK buffer (100 mM
NaCl, 0.5% Triton X-100, 300 mM sucrose, 3 mM MgCl
 
2
 
, 10 mM Pipes,
pH 6.8) containing 2 mM PMSF, 50 mM sodium fluoride, 1 mM sodium
orthovanadate, and protease inhibitor mixture (Boehringer Mannheim).
The homogenates were clarified by centrifugation at 20,000 
 
g
 
 for 15 min at
4
 
8
 
C. Immunoprecipitates were suspended in reducing or nonreducing
sample buffer, heated to 100
 
8
 
C for 5 min, resolved in 8 or 10% SDS–poly-
acrylamide gels (Novex), and electrophoretically transferred to nitrocellu-
lose membrane (Novex) for 1.5 h at 150 mA. The filters were incubated
with blocking buffer (5% nonfat dry milk; alternatively, 5% BSA for an-
tiphosphotyrosine antibody in T-TBS[150 mM NaCl, 50 mM Tris-HCl,
0.1% Tween 20, pH 7.4]) for 1 h. Immunoblots for phosphotyrosine, acti-
vated ERK2, GFP, Shc, or other epitopes were visualized by the ECL sys-
tem and Hyperfilm X-ray film (Amersham).
 
Protein Phosphatase Assays
 
PTEN dephosphorylation of Shc and FAK were examined using an in blot
phosphatase assay as described (Tamura et al., 1998). In brief, histidine-
 
tagged PTEN (His
 
6
 
-PTEN) was generated by inserting full-length PTEN
cDNA into the pQE30 vector (Qiagen). The expressed recombinant pro-
tein was purified using Ni-NTA beads (Qiagen) under denaturing condi-
tions, and then renatured by sequential dilution and concentration in
renaturation buffer (PBS, pH 7.0, containing 2 mM MgCl
 
2
 
, 0.5 mM PMSF,
0.005% Tween 20, 10 mM DTT, protease inhibitor cocktail). Purity
(
 
.
 
90%) was confirmed by SDS-PAGE and Coomassie blue staining.
Phosphorylated FAK was obtained from immunoprecipitates using anti-
FAK antibody from cell lysates of U-87MG cells that had spread on fi-
bronectin for 1 h. Phosphorylated Shc and activated ERK2 were isolated
as immunocomplexes from cell lysates of EGF-stimulated (10 ng/ml for 5
min) U-87MG cells transfected with Flag-Shc and HA-ERK2, and then
immunoprecipitated using either anti-Flag or anti-HA antibodies, respec-
tively. Immunoprecipitated FAK and Shc were mixed and subjected to
8% SDS-PAGE. Immunoprecipitates of ERK2 using anti-HA were sub-
jected to 10% SDS-PAGE, and then electrotransferred to nitrocellulose.
Blots were incubated with 20 
 
m
 
g/ml recombinant His
 
6
 
-PTEN in 100 mM
Tris buffer, pH 7.0, containing 10 mM MgCl
 
2
 
, and 10 mM DTT at 30
 
8
 
C for
30 min. Phosphorylation of Shc and FAK was detected with RC20 an-
tiphosphotyrosine antibody and activated ERK2 was detected by anti–
phospho-ERK2 antibody.
PTEN phosphatase activity against all three isoforms of endogenous
Shc was also examined under nondenaturing conditions in vitro using im-
munoprecipitated Shc before SDS-PAGE. Endogenous Shc was isolated
from EGF-stimulated, nontransfected U-87MG cells homogenized in lysis
buffer as described above by immunoprecipitation using anti-Shc mAb (4
 
m
 
g/ml) and GammaBind G–Sepharose beads (Amersham Pharmacia Bio-
tech) for 3 h at 4
 
8
 
C. The immunocomplexes were incubated with 0.5 
 
m
 
g re-
combinant PTEN in 30 
 
m
 
l of 50 mM Tris buffer, pH 7.0, containing 50 mM
NaCl and 10 mM DTT at 30
 
8
 
C for 30 min. Controls were incubated
without PTEN or with PTEN plus 2 mM sodium vanadate. The reaction
was terminated by adding nonreducing SDS sample buffer and heating at
100
 
8
 
C for 5 min. After SDS-PAGE, immunoblotting was carried out us-
ing RC20 antiphosphotyrosine mAb.
 
Cell Motility
 
After puromycin selection, cells expressing various constructs were re-
plated on 50-mm glass microwell dishes (Mattek Corp.) coated with 10 
 
m
 
g/ml
fibronectin and cultured overnight in DME containing 10% FBS. Cell
movements were monitored using a Zeiss inverted microscope. Video im-
ages were collected with a CCD camera (model 2400; Hamamatsu Photon-
ics) at 20-min intervals, digitized, and stored as image stacks using Meta-
Morph Group 3.5 software (Universal Imaging Corp.). Image stacks were
converted to QuickTime movies, the positions of nuclei were tracked to
quantify cell motility, and their velocities were calculated in micrometers
at 20-min points using the same software. Similar results with nonselected
cells were obtained in preliminary experiments using GFP-tagged FAK or
GFP-Shc and tracking of cell migration using time-lapse fluorescence mi-
croscopy. For testing the effects of PD98059 (a specific MEK1 inhibitor)
and wortmannin (a phosphatidylinositol 3
 
9
 
-kinase inhibitor) on cell mi-
gration, we cultured the cells in 20 
 
m
 
M PD98059 or 30 nM wortmannin
for 2 h, and then examined cell motility for three more hours with each
inhibitor.
 
Immunofluorescence Microscopy
 
Glass coverslips (12 mm; Carolina Biological Supply Company) were in-
cubated with 10 
 
m
 
g/ml fibronectin in PBS overnight at 4
 
8
 
C. The coverslips
were blocked with 10 mg/ml BSA for an additional 1 h at 37
 
8
 
C. After
puromycin selection, cells expressing various constructs were replated on
the coverslips and cultured overnight in DME containing 10% FBS.
Thereafter, the cells were fixed with 4% paraformaldehyde in PBS for 20
min, and then permeabilized with 0.5% Triton X-100 in PBS for 5 min.
Focal adhesions were visualized by incubating first with mouse antipaxil-
lin mAb, and then with Cy3-conjugated goat antibody to mouse immuno-
globulin G. Actin filaments were stained with rhodamine-phalloidin. For
semi-quantitative documentation of cytoskeletal organization, a square
equivalent to 15 
 
3 
 
15 
 
m
 
m was overlaid randomly over each of the four
quadrants of each cell. Rhodamine-phalloidin–stained actin microfila-
ments in each square were scored as appearing random or oriented in par-
allel. In this assay, the highest index for a cell occurs when all four test
fields show oriented actin microfilaments, resulting in a maximal index
score of 4.0. 
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Results
 
We examined for roles of Shc in regulating cell migration,
because it is implicated in integrin signaling and is a prom-
inent target of the tumor suppressor phosphatase PTEN,
which is a newly identified regulator of cell migration and
invasion. We find that Shc can enhance cell migration in-
hibited by PTEN and that Shc is a direct target for PTEN
phosphatase activity. We compare this novel pathway reg-
ulating cell migration both mechanistically and biologi-
cally with the previously described FAK-p130
 
Cas
 
 pathway
(Cary et al., 1996, 1998; Tamura et al., 1998) including
roles in regulating speed and the directionality of cell mi-
gration.
 
Shc Induces Cell Migration Inhibited by PTEN
 
To test for a role of Shc in cell migration modulated by
PTEN, we cotransfected PTEN and puromycin resistance
plasmids with Shc (or FAK as a positive control), and se-
lected transfectants for 2 d using puromycin. This puromy-
cin selection procedure routinely yielded 
 
z
 
90% pure
populations of transfectants according to fluorescence
analyses using GFP markers. The surviving selected cells
were replated on glass microwell dishes coated with 10 
 
m
 
g/ml
fibronectin and cultured in DME containing 10% FBS
overnight. To analyze cell motility, phase-contrast video
images were recorded at 20-min intervals using a CCD
camera and were analyzed for velocities of cell migration
using MetaMorph image processing software. As shown in
Fig. 1, reconstitution of PTEN in these cells lacking PTEN
to protein levels similar to those in primary fibroblasts
(1–2
 
3
 
 according to immunoblotting) substantially inhibited
cell movement. Migration was reduced to 39% of rates in
controls without PTEN. Interestingly, coexpression of Shc
with PTEN significantly rescued rates of cell motility on fi-
bronectin, raising them from 39% of control migration
rates with PTEN alone to 78% of controls after Shc coex-
pression with PTEN. These differences were significant at
the
 
 P 
 
, 
 
0.001 level.
Because PTEN can downmodulate the ERK type of
MAP kinase signaling, we tested whether constitutively
activated MEK1, a potential downstream effector of Shc,
could also activate cell movement downmodulated by
PTEN (Fig. 1). MEK1 coexpression was highly effective in
reversing PTEN inhibition of migration (significant at the
 
P 
 
, 
 
0.001 level). Consistent with previous observations
that FAK and p130
 
Cas 
 
overexpression could rescue PTEN
inhibition of cell migration measured by in vitro wound-
healing assays (Tamura et al., 1999a), FAK and p130
 
Cas
 
also effectively rescued single cell movement in this sys-
tem (Fig. 1). To test whether Shc and FAK stimulated cell
motility via different or overlapping pathways, we per-
formed a triple transfection experiment combining PTEN
with both Shc and FAK. Cell movement was fully restored
to 95% of controls by this triple transfection, as compared
with 78% of controls for Shc plus PTEN double transfec-
tion and 82% for FAK plus PTEN. This simple additivity
of migration suggests the existence of two parallel biologi-
cal pathways originating from Shc and FAK affecting cell
migration modulated by PTEN. In contrast, the Y397F
mutant of FAK lacking the Src and phosphatidylinositol
3
 
9
 
-kinase binding site did not affect migration rates (data
not shown).
 
Dominant Negative Shc Expression Inhibits
Cell Migration
 
As a direct test of the role of Shc in cell migration (inde-
pendent of PTEN), we examined whether expression of a
dominant negative mutant of Shc to block endogenous Shc
function could mimic the effects of PTEN. Transfection
with dominant negative Shc (double point mutant Y239/
317F) substantially reduced cell migration to 58% of con-
trols (Fig. 2). A putative integrin-specific mutant of Shc in
which only tyrosine 317 was mutated (Wary et al., 1998)
produced less inhibition, suggesting a roughly 40:60% ra-
tio of contributions of integrins versus serum growth fac-
tors to Shc stimulation of migration. Specifically, there was
16% inhibition with Y317F versus 42% inhibition with the
double mutant. 
In addition, transfection with FRNK or dominant nega-
tive p130
 
Cas
 
 also substantially reduced cell migration to 55
or 54% of controls, respectively (Fig. 2). In contrast, ex-
pression of GFP (
 
2
 
), Shc, FAK, constitutively activated
MEK1, or p130
 
Cas 
 
alone in the absence of PTEN had little
or no effect on cell migration of U-87MG cells in this sys-
tem (Fig. 2). Because it had been reported previously that
FAK overexpression significantly increases CHO cell mi-
gration (Cary et al., 1996), we also compared FAK overex-
Figure 1. Shc accelerates cell movement inhibited by PTEN.
U-87MG cells were transfected with various plasmids as indicated
and transfectants were selected by puromycin as described in
Materials and Methods. Cell movements were monitored by
time-lapse video microscopy and motility was calculated as veloc-
ity (mm/3 h) using image processing software as described in Ma-
terials and Methods. Data from at least 10 cells selected by puro-
mycin were collected and calculated in each experiment, and data
were pooled from three independent experiments (each with
similar results). Error bars indicate SD for at least 30 cells per
condition. One asterisk, P , 0.001 versus controls transfected
with GFP-PTEN only. Two asterisks, P , 0.01 versus each of the
other conditions (except for control transfected with GFP-PTEN
only or without plasmid). 
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pression in CHO cells using our cell migration assay. We
found that FAK overexpression did enhance cell migra-
tion of CHO cells in this system to 165% of controls trans-
fected with GFP (
 
2
 
) alone (data not shown).
Although phosphatidylinositol 3
 
9
 
-kinase, an upstream
regulator of PKB/Akt, has been implicated in cell move-
ment (Keely et al., 1997; Shaw et al., 1997; Sander et al.,
1998), to our knowledge there are no studies on the roles
of Akt in cell movement. Because many studies indicate
that PTEN inhibits cell growth and leads to apoptosis
through inhibition of the PKB/Akt pathway, an obvious
question is whether PTEN-mediated inhibition of Akt af-
fects cell migration. U-87MG cells were cotransfected with
the puromycin resistance plasmid pHA262pur and either
wild-type Akt or dominant negative Akt, and transfected
cells were selected as described above. We could not de-
tect any significant differences in rates of cell migration
between control cells and either type of transfectant af-
fecting Akt (data not shown). Effects of PTEN on Akt are,
therefore, not likely to play a role in PTEN regulation of
cell migration.
 
Shc Interacts Physically with PTEN
 
Since Shc and PTEN appeared to be involved in an early
step of a specific signaling pathway regulating cell migra-
tion, they might be expected to interact physically. Shc has
three isoforms of 66, 52, and 46 kD, which are derived
from alternative splicing and differential translation initia-
tion at three ATG sites (Migliaccio et al., 1997). PTEN
preferentially decreases tyrosine phosphorylation of the
52-kD isoform of Shc and thereby inhibits interaction with
the adapter protein Grb2, resulting in decreased activation
of the Ras/Raf/MEK/ERK pathway (Gu et al., 1998). Be-
cause phosphatases bind, but rapidly cleave and dissociate
from substrates, we tested for physical interactions of
PTEN with Shc in living cells using a trapping mutant
D92A of PTEN. The latter mutant has inactivated phos-
phatase activity but retains its ability to bind and even to
protect a substrate (Flint et al., 1997). Cells were cotrans-
fected with control or PTEN plasmids and a puromycin re-
sistance plasmid, and then selected with puromycin to en-
Figure 2. Dominant negative Shc inhibits cell motility. U-87MG
cells were cotransfected with pHA262pur and GFP (2) with or
without various plasmids and transfectants were selected as de-
scribed in Materials and Methods. Shc (Dn) indicates the domi-
nant negative Y239/317F Shc plasmid, Shc (Wt) indicates wild-
type Shc, FRNK is a dominant negative FAK truncation, and
P130Cas (Dn) indicates the DSD-p130Cas dominant negative mu-
tant of p130Cas lacking the substrate domain. Cell motility was ex-
amined as described in Fig. 1. Error bars indicate SD for at least
30 cells per condition. Asterisk, P , 0.001 versus controls trans-
fected with GFP (2) only.
Figure 3. Physical interaction of PTEN with Shc. U-87MG cells
were cotransfected with plasmids containing pHA262pur and
GFP tag without PTEN (Vec), GFP-tagged wild-type PTEN
(Wt), PTEN trapping mutant D92A, or inactivated phosphatase
PTEN mutant C124A (20 mg each), and then selected with puro-
mycin as described in Materials and Methods. After selection,
cells were stimulated with EGF for 5 min, and then solubilized in
modified CSK buffer as described in Materials and Methods. The
cell lysates were immunoprecipitated with either anti-Shc (IP:
Shc) or anti-GFP (IP: GFP) antibody and immunoblotted for
anti-GFP (IB: GFP) or anti-Shc (IB: Shc) antibody. (A) Immu-
noprecipitates containing endogenous Shc immunoblotted with
either anti-GFP (top panel) or anti-Shc antibody (bottom panel).
(B) Immunoprecipitated GFP-tagged proteins immunoblotted
with either anti-Shc antibody (top panel) or anti-GFP antibody
to confirm equivalent expression of PTEN mutant proteins (bot-
tom panel). Expression levels of GFP (2) lacking PTEN (Vec)
were two to threefold higher than that of GFP-PTEN (data not
shown). 
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rich transfected cells. The surviving cells (90% positive)
were cultured overnight without puromycin, and then
stimulated with EGF for 5 min. Homogenates were immu-
noprecipitated with anti-Shc or anti-GFP followed by im-
munoblotting with the opposite or the same antibody.
As shown in Fig. 3 A, immunoprecipitated Shc retained
substantial amounts of bound PTEN D92A trapping mu-
tant. It also retained, to a lesser extent, the direct active
site PTEN mutant C124A. But in cells transfected with
control plasmid GFP (
 
2
 
) or wild-type GFP-PTEN, such
associations with Shc could not be detected. Conversely,
immunoprecipitation of the GFP-PTEN mutant D92A
with anti-GFP antibody also retained Shc bound in higher
quantities as compared with cells expressing the C124A
mutant or wild-type PTEN (Fig. 3 B). These results using a
substrate-trapping mutant strongly suggest that PTEN di-
rectly interacts with Shc. PTEN associated selectively with
the 52-kD isoform of Shc (Fig. 3 B), which is consistent
with the higher tyrosine phosphorylation of this 52-kD iso-
form. Similar but much weaker binding of the D92A
PTEN trapping mutant to Shc was observed even in the
absence of stimulation by EGF with minimal binding of
wild-type or C124A mutant PTEN (data not shown).
 
PTEN Directly Dephosphorylates Shc
 
Next, we tested whether PTEN could directly dephosphor-
ylate Shc using two types of in vitro phosphatase assays.
An in blot phosphatase assay was used to examine the ty-
rosine-phosphorylated 52-kD isoform of Shc as a direct
substrate of PTEN. FAK was used as a positive control
(Tamura et al., 1998) and activated ERK2 as a negative
control (Myers et al., 1997). Renatured recombinant
PTEN reduced the tyrosine phosphorylation of the elec-
troblotted 52-kD Shc by 67% (Fig. 4 A, lane 2, top) com-
pared with controls to which we added 2 mM sodium van-
adate, a general inhibitor of phosphatase activity (lane 1).
This level of dephosphorylation of Shc was similar to the
70% reduction in tyrosine phosphorylation of FAK. In
contrast, PTEN could not dephosphorylate activated
ERK2 in vitro (Fig. 4 A, lane 2, bottom); the latter nega-
tive result was consistent with a previous report using a
different assay system (Myers et al., 1997).
We also tested whether PTEN could dephosphorylate
native tyrosine–phosphorylated Shc in vitro. Incubation of
recombinant PTEN with immunoprecipitated endogenous
Shc showed that PTEN could dephosphorylate all three
isoforms of Shc (Fig. 4 B). PTEN appeared to dephosphor-
ylate both of the two major tyrosine phosphorylation sites
because it equally effectively removed phosphotyrosine
from mutant p52Shc molecules containing only one of the
two sites after point mutations to phenylalanine in the
Y239F or Y317F mutants (Fig. 4 C). The double point mu-
tant Y239/317F Shc showed only very weak phosphoryla-
tion stimulated by EGF (data not shown), confirming that
tyrosines 239 and 317 were the two major sites for phos-
phorylation.
 
Shc Overexpression Rescues Integrin-mediated MAP 
Kinase Activation Impaired by PTEN
 
The possible mechanisms of Shc regulation of PTEN-mod-
ulated adhesion were explored in more detail. We tested
whether overexpression of Shc or FAK could attenuate
the effects of PTEN on MAP kinase activation by fi-
bronectin. We cotransfected GFP-PTEN and puromycin
resistance plasmids with or without Shc or FAK, or with
both Shc and FAK, and selected for transfectants using
puromycin. The surviving selected cells were plated for 10
min on dishes coated with fibronectin, and then homoge-
nized using lysis buffer. MAP kinase activation was as-
sayed by direct examination of ERK1/2 phosphorylation
by immunoblotting with anti–phospho-ERK1/2. MAP ki-
nase activation was substantially suppressed in cells trans-
fected with PTEN alone, as described previously (Gu et al.,
Figure 4. Direct tyrosine dephosphorylation of Shc by PTEN.
The capacity of PTEN to dephosphorylate Shc was evaluated ei-
ther by an in blot tyrosine phosphatase assay using the trans-
fected 52-kD isoform of PTEN or its mutants (A and C) or by an
in vitro phosphatase assay using immunoprecipitated (IP), native
Shc isoforms of 46, 52, and 66 kD followed by immunoblotting
(IB) for phosphotyrosine (B). For A and C, U-87MG cells were
transiently transfected with Flag-tagged 52-kD isoform of wild-
type Shc (Wt), Y239F mutant, Y317F mutant, or HA-ERK2. 24 h
after transfection, cells were stimulated by EGF for 5 min, and
then immunoprecipitated (IP) with anti-Flag or anti-HA. For B,
endogenous Shc was immunoprecipitated with anti-Shc mAb af-
ter nontransfected cells were stimulated by EGF for 5 min. En-
dogenous FAK was immunoprecipitated after stimulation by
adhesion to fibronectin for 1 h as described in Materials and
Methods. In A, immunoprecipitated FAK and Shc (wild-type)
were mixed and subjected to 8% SDS-PAGE; immunoprecipi-
tated ERK2 was analyzed using 10% SDS–polyacrylamide gels.
After electroblotting, strips of blots were incubated with recom-
binant PTEN with (lane 1) or without (lane 2) 2 mM sodium van-
adate at 308C for 30 min. Shc and FAK phosphorylation were de-
tected with antiphosphotyrosine antibody (A, top panels), and
phospho-ERK2 was detected by anti–phospho-ERK1/2 antibody
(A, bottom panels). Immunoprecipitates of endogenous Shc (B)
and 52-kD isoform of wild-type or mutants (C) were directly in-
cubated with 0.5 mg of renatured recombinant PTEN for 30 min
at 308C. The reaction mixtures were subjected to 8% SDS-PAGE
for Western immunoblotting. Shc tyrosine phosphorylation was
detected by an antiphosphotyrosine mAb. 0, no additions; 1,
incubated with recombinant PTEN plus 2 mM sodium vanadate;
and 2, recombinant PTEN without sodium vanadate. The same
quantities of total protein were loaded in each lane.Gu et al. Shc, FAK, and PTEN Regulate Cell Motility and Persistence 395
1998) (Fig. 5 A, increases of only 1.2–1.3-fold after plating
on fibronectin). However, co-overexpression of PTEN
with Shc resulted in an increase of MAP kinase activation
by 2.9-fold 10 min after plating on a fibronectin substrate
compared with levels in cells maintained in suspension
(Fig. 5 A). In comparison, control cells transfected with
GFP (2) alone (no GFP-PTEN) showed a similar 2.5-fold
increase in ERK activation after fibronectin stimulation
(data not shown).
The changes in MAP kinase activation accompanying
overexpression of Shc in PTEN-reconstituted cells were
associated with increases in Shc tyrosine phosphorylation
as shown in Fig. 5 B. In contrast, overexpression of FAK
produced little or no change in Shc tyrosine phosphoryla-
tion (Fig. 5 B), even though it substantially enhanced FAK
phosphorylation (Fig. 6 A). These results in U-87MG cells
differ from findings in 293 cells in which FAK overexpres-
sion produced elevated Shc phosphorylation and MAP ki-
nase activation (Schlaepfer and Hunter, 1997; Schlaepfer
et al., 1998). We confirmed that transfection of FAK in 293
cells indeed produced elevated Shc phosphorylation (two-
fold) and MAP kinase activation; however, the levels of
overexpression differed markedly in the two cell systems,
with a two to threefold increase in total FAK levels in
U-87MG cells and .10-fold increases in 293 cells, which
may account for the differences (Figs. 5 and 6, and data
not shown).
Shc Overexpression Does Not Affect FAK and
p130Cas Phosphorylation
The activation of integrins by cell binding to extracellular
matrix leads to increases in both Shc and FAK phosphory-
lation and enhances signaling pathways. We tested for
possible overlaps between the Shc and FAK pathways by
examining for effects of Shc overexpression on the
FAK-p130Cas activation pathway by comparing FAK and
p130Cas phosphorylation levels in U-87MG cells cotrans-
fected with PTEN and Shc or FAK. As shown in Fig. 6 A,
Shc overexpression did not increase FAK phosphoryla-
tion, which remained at levels similar to controls trans-
fected with PTEN alone; in contrast, FAK overexpression
clearly enhanced FAK phosphorylation as previously re-
ported (Tamura et al., 1999a). Examining downstream
p130Cas phosphorylation, FAK overexpression substan-
tially enhanced p130Cas phosphorylation but Shc overex-
pression could not (Fig. 6 B). These results support the hy-
pothesis that two separate pathways originating from Shc
or from FAK are downregulated by PTEN.
Shc and FAK Regulate Cell Migration via
Distinct Pathways
Cell migration was measured by time-lapse video micros-
copy and tracking of patterns of motility. Fig. 7 A, a, shows
a representative set of motility records of U-87MG cells.
PTEN inhibited movement of individual cells (Fig. 7 A, b),
which is consistent with previous results (Tamura et al.,
1999a). Unexpectedly, we found that Shc and FAK each
Figure 5. Effects of Shc or FAK overexpression on MAP kinase
activation and Shc phosphorylation inhibited by PTEN. U-87MG
cells were cotransfected with pHA262pur and GFP-PTEN with
or without Flag-Shc or HA-FAK. After selection using puromy-
cin, cells were serum-restricted overnight in 0.2% FBS. Cells
were detached and incubated in serum-free medium for 30 min at
378C as described under Materials and Methods. (A) For assay-
ing MAP kinase activation, the cells were either maintained in
suspension (2) or allowed to attach to fibronectin-coated dishes
for 10 min (1), which is the time of maximal activation in these
cells (Gu et al., 1998). Cell lysates were subjected to 10% SDS-
PAGE. After electroblotting, blots were analyzed using anti–
phospho-ERK1/2 antibody (top), and total quantities of ERK1/2
were confirmed using anti-ERK1/2 antibody (bottom). (B) After
selection by puromycin, cells were either maintained in suspen-
sion (2) or allowed to attach to fibronectin-coated dishes for 30
min (1). Total Shc was immunoprecipitated with anti-Shc mAb,
and then immunoblotted with antiphosphotyrosine (top) or total
Shc (bottom). The level of Shc overexpression (52 kD) was in-
creased 2.7-fold as compared with endogenous Shc (52 kD) as de-
termined by densitometry. Ctr, control transfected with PTEN;
and Vec, vector control transfectant without PTEN. The lanes la-
beled Shc, FAK, or Shc 1 FAK were cotransfected with PTEN
plus the indicated expression plasmids.
Figure 6. Shc overexpression does not affect FAK and p130Cas
phosphorylation. Cell lysates were prepared from cells cotrans-
fected with PTEN and the indicated plasmids (labels at top) in
suspension (2) or on fibronectin substrates (1) as described in
Fig. 5. Proteins were immunoprecipitated from the lysates with
either FAK or p130Cas antibodies, and then immunoblotted with
antiphosphotyrosine. (A) Phospho-FAK (P-FAK, top) and total
FAK (T-FAK, bottom); and (B) phospho-p130Cas (top) and total
p130Cas (bottom). The level of FAK overexpression in FAK
transfectants was increased 2.5-fold according to densitometry.The Journal of Cell Biology, Volume 146, 1999 396
regulated cell movement in a different manner. In cells
cotransfected with Shc and PTEN, the cells moved more
rapidly but in random directions with a relatively limited
number of runs that persisted in the same direction (Fig. 7
A, c). In contrast, in cells cotransfected with FAK and
PTEN, the cells tended to continue to migrate in a particu-
lar direction, i.e., persistent movement (Fig. 7 A, d).
To quantify these differences in migration patterns, we
compared the ratios of the shortest direct distance from
the starting point of each recording to the end point (D),
to the total distance traversed by the cell (T). For ease of
comparisons, the ratio D/T was normalized to a value of
1.0 for cells transfected with PTEN alone. As shown in Fig.
7 B, cotransfection of Shc with PTEN substantially re-
duced the ratio to 54% compared with controls trans-
fected with PTEN alone. However, cotransfection by
PTEN with FAK significantly increased the D/T value by
1.75-fold over controls transfected with PTEN alone. In-
terestingly, cotransfection of both Shc and FAK with
PTEN resulted in an apparent reconstitution to a ratio
characteristic of nontransfected cells (Fig. 7 B): the ratio
was z1.25-fold higher than with PTEN alone, which rep-
resented restoration of the original ratio observed in con-
trol cells transfected with GFP (2) vector alone (i.e., no
PTEN, Shc, or FAK transfection). The differences be-
tween the triple transfection (PTEN, Shc, and FAK) and
double transfections (PTEN and Shc or PTEN and FAK)
were significant at the P , 0.0005 and P , 0.001 levels, re-
spectively. Furthermore, overexpression of constitutively
activated MEK1 to enhance MAP kinase activation mim-
Figure 7. Shc and FAK reconstitute
different aspects of PTEN-inhibited
cell migration. (A) Representative ex-
amples of cell movements on fibronec-
tin tracked at 20-min intervals over a
span of 3 h. (a) Cells transfected with
GFP (2) as a control; (b) cells trans-
fected with GFP-PTEN only; (c) cells
transfected with GFP-PTEN and Shc;
and (d) cells transfected with GFP-
PTEN and FAK. (B) Quantitation of
persistence of migratory directional-
ity. Relative D/T ratios represent the
ratios of the direct distance from start
point to end point (D) divided by the
total track distance (T), expressed rela-
tive to the ratio after GFP-PTEN
transfection alone (value set 5 1.0).
Error bars indicate SD of results
pooled from three independent experi-
ments (each with similar results and a
total of at least 30 cells per condition).
Asterisk, P , 0.0005 versus control
transfected with GFP-PTEN alone.
Two asterisks, P , 0.0005 versus sam-
ples cotransfected with GFP-PTEN
plus Shc or activated MEK1 and also
P , 0.001 versus samples cotransfected
with GFP-PTEN and FAK or p130Cas.
(C) Plot of mean square displacement
against time. The net displacement (D)
was measured every 40 min from start
to end point. Error bars indicate SEM.
At least 15 cells were measured for
each point. Open circles represent the
cells cotransfected with GFP-PTEN
plus FAK and closed circles represent
cells cotransfected with GFP-PTEN
plus Shc. Note that the x-intercept for
Shc transfectants is substantially closer
to the origin than in the intercept for
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icked the actions of Shc and reduced the ratio as shown in
Fig. 7 B. In contrast, overexpression of p130Cas produced
effects similar to FAK and increased the ratio. Finally,
even though transfection of cells with the dominant nega-
tive Shc construct reduced the speed of cell migration (Fig.
2), it resulted in a 1.5-fold increase in the D/T ratio (data
not shown). These results strongly suggest that PTEN in-
hibits cell movement through at least two different path-
ways, i.e., Shc–MAP kinase and FAK-p130Cas.
To confirm random versus directional cell motility, we
used a mean square displacement assay (Gail, 1973). Net
displacements (D) of cells from their location at time zero
of video time-lapse microscopy was determined every 40
min and the mean square displacement (D2) was calcu-
lated and plotted against time as shown in Fig. 7 C. In pure
random movement, the plot would be a straight line pass-
ing through the origin. The x-intercept for Shc was much
closer to the origin than the intercept for FAK, indicating
that Shc promotes relatively random movement, whereas
FAK promotes considerably more directional migration.
Additional Evidence for Separate Shc and
FAK Pathways
Overexpression of FAK in U-87MG cells did not signifi-
cantly increase the level of tyrosine phosphorylation of
Shc (Fig. 5 B) even though total phosphorylated FAK was
considerably increased (Fig. 6 A). Dominant negative
(dominant interfering) mutants of FAK, Cas, and Shc
were used to test further the extent of separation of FAK
and Shc pathways regulating migratory speed or direction-
ality. U-87MG cells were cotransfected with PTEN to sup-
press migration, and then Shc or FAK cotransfectants
were probed for specificity of each pathway using domi-
nant negative FAK (the truncated version of FAK termed
FRNK), dominant negative Cas (missing the substrate do-
main), or dominant negative Shc (Y239/317F). There were
no significant effects of FRNK and dominant negative Cas
on Shc-promoted cell motility: overexpression of Shc in
PTEN-transfected cells plus FRNK or dominant interfer-
ing Cas cotransfection produced minimal effects on cell
motility (Table I). Furthermore, D/T ratios were also only
minimally affected compared with parallel transfectants
without FRNK or dominant interfering Cas (Table I).
Conversely, dominant negative Shc cotransfected with
FAK or p130Cas also resulted in minimal effects on either
rates of cell motility or the increase of D/T ratios depen-
dent on the FAK pathway (Table I). These results reveal
only minimal effects of Shc on the FAK-p130Cas pathway,
whereas the same dominant negative Shc construct had
substantial effects on migration when both putative path-
ways were active (Fig. 2).
Additional evidence for differences between the FAK
and Shc pathways was provided by the use of MEK and
phosphatidylinositol 39-kinase inhibitors. The specific MEK
inhibitor PD98059 abolished the increase in cell migration
dependent on Shc (cells reconstituted with PTEN and
cotransfected with Shc), producing a 96% reduction in cell
motility compared with untreated controls (Table II). In
clear contrast, there was no significant inhibition (10%) of
cell migration by PD98059 in parallel cells cotransfected
with FAK and PTEN (Table II). Furthermore, the phospha-
tidylinositol 39-kinase inhibitor wortmannin substantially
inhibited cell migration activated by FAK overexpression,
producing a 65% reduction in rates of FAK-induced cell
motility (Table II). A very recent report describes a simi-
lar inhibition by phosphatidylinositol 39-kinase inhibitors
of migration enhanced by FAK overexpression in CHO
cells (80% inhibition; Reiske et al., 1999). In contrast,
wortmannin had much less effect on our Shc-overexpress-
ing cells, with a modest 23% decrease in the increased mi-
gration because of Shc.
Since a FAK-independent Src family kinase pathway
has been described for the tyrosine phosphorylation of Shc
(Sieg et al., 1998; Wary et al., 1998), we examined for pos-
sible effects of Src-related kinase activity on migration in
these cells. Inhibition of function of Src kinases by the use
of Csk overexpression had minimal inhibitory effects on
the FAK pathway (FAK-overexpressing cells), with mi-
gration rates of 117 6 24 mm/3 h in controls compared with
105 6 25 mm/3 h in Csk-overexpressing cells; there were no
detectable effects of Csk overexpression on Shc-enhanced
motility. In these experiments, Csk transfection resulted in
a 7-fold increase in Csk protein by Western blotting and a
2.5-fold enhancement of Src tyrosine phosphorylation, but
no evidence for significant roles of Src in regulating migra-
tion of these cells could be demonstrated.
Table I. Minimal Cross-inhibition by Dominant
Negative Inhibitors
Transfectant
Additional
plasmid Migration rate 6 SD Directionality
mm/3 h D/T ratio
PTEN 1 Shc None 110 6 24 0.57 6 0.20
PTEN 1 Shc FRNK 101 6 20 0.53 6 0.25
PTEN 1 Shc Dn-Cas 105 6 18 0.50 6 0.20
PTEN 1 FAK None 117 6 24 1.72 6 0.14
PTEN 1 FAK Dn-Shc 104 6 21 1.81 6 0.16
PTEN 1 Cas None 118 6 23 1.65 6 0.17
PTEN 1 Cas Dn-Shc 108 6 18 1.82 6 0.18
U-87MG cells were cotransfected with PTEN plus the indicated plasmids, and then
analyzed by video time-lapse microscopy and image analysis for rates of cell migra-
tion and directionality as described in Materials and Methods. Dn-Cas, dominant nega-
tive Cas plasmid DSD-p130Cas lacking the substrate domain. Dn-Shc, dominant nega-
tive Shc plasmid Y239/317F with a double mutation in tyrosine phosphorylation sites.
These dominant interfering plasmids substantially inhibited migration in cells in which
the FAK and Shc pathways were not inhibited by PTEN (see Fig. 2).
Table II. Effects of Inhibitors on Shc- or
FAK-induced Migration
Transfectant Inhibitor Migration rate 6 SD
Increase vs.
PTEN
Percentage
inhibition
mm/3 h mm/3 h
PTEN None 54 6 17 — —
PTEN 1 Shc None 110 6 24 56 0%
PTEN 1 Shc PD98059 56 6 18 2 96%
PTEN 1 Shc Wortmannin 99 6 18 43 23%
PTEN 1 FAK None 117 6 24 63 0%
PTEN 1 FAK PD98059 111 6 15 57 10%
PTEN 1 FAK Wortmannin 76 6 65 22 65%
U-87MG cells, transiently transfected with the indicated expression plasmids, were
treated with inhibitors or left untreated, and then were analyzed for rates of cell migra-
tion as described in Materials and Methods. The column entitled Increase shows net
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FRNK and Dominant Negative p130Cas Inhibit the 
Directionally Persistent Component of Movement 
Remaining in the Absence of Serum
To evaluate the contribution of growth factor stimulation
to the Shc pathway stimulated by integrin ligation (as in
Fig. 5B), we measured cell movements in the absence of
FBS. Cell migration rates were reduced to z64% of con-
trols in the presence of serum and the directionality of mi-
gration of the cells became markedly persistent in serum-
free medium, as shown in Fig. 8 A (Ctr). Consistent with
the prediction that this residual directional component of
migration would be FAK-dependent, transfection by the
FAK dominant negative construct termed FRNK or by
dominant negative Cas resulted in inhibition of migration
(Fig. 8, A and B, FRNK and Dn-Cas [Dn-p130Cas]). The
differences between transfection with vector alone (Ctr)
and transfection with FRNK or dominant negative Cas
were significant at the P , 0.0001 level. Moreover, overex-
pression of FRNK or dominant negative Cas also substan-
tially reduced the directionality of migration, as indicated
by a decrease in D/T ratios, which was also significant at
the P , 0.0001 level.
In contrast, transfection with dominant negative Shc had
only minor effects on this FAK-dependent form of cell
motility (Figs. 8, A–C). Taken together, these findings in
Figs. 5 and 8 suggest that the Shc pathway in U-87MG cells
involves both integrins and growth factors for Shc phos-
phorylation and its downstream effects, and that there are
at least two distinct pathways regulating cell motility.
These findings appear to be consistent with a previous re-
port that Ras signaling (presumably including MAP kinase
signaling) is involved in cell migration stimulated by
PDGF (Kundra et al., 1994), yet cells expressing dominant
negative Ras were still able to migrate on fibronectin
(Kundra et al., 1995), which could have been due to in-
volvement of the FAK-p130Cas pathway.
Shc and FAK Overexpression Have Different Effects on 
Actin Cytoskeleton and Focal Adhesions
Our previous studies had indicated that PTEN affects cell
migration and invasion on fibronectin and had shown that
FAK or p130Cas could rescue these functions (Tamura et al.,
1999a). Moreover, transfection of constitutively activated
MEK1 to induce MAP kinase activity could partially res-
Figure 8. Dominant negative Shc and FRNK have different effects
on cell migration in the absence of FBS. U-87MG cells were trans-
fected with vector alone (Ctr) or dominant negative (Dn) plasmids
of Shc, FAK, or p130Cas as indicated (Y239/317F Shc, the FRNK
truncation of FAK, or DSD-p130Cas, respectively) and transfectants
were selected by puromycin. After selection, cells were replated on
fibronectin-coated dishes overnight without FBS. (A) Representa-
tive examples of cell movements on fibronectin tracked for 3 h
without FBS. (B) Cell motility was calculated as velocity (mm/3 h).
Data were collected from at least 20 cells from three independent
experiments (each with similar results). Error bars indicate SD. (C)
Quantitation of persistence of migratory directionality. The calcula-
tion of D/T ratios was performed as described for Fig. 7. The rela-
tive ratio value of vector (Vec) transfection alone was set as 1.0. Error bars indicate SD of results pooled from three independent
experiments. Asterisk, P , 0.0001 versus control transfected with vector alone.Gu et al. Shc, FAK, and PTEN Regulate Cell Motility and Persistence 399
cue cell spreading impaired by PTEN (Gu et al., 1998). In
this study, Shc was found to enhance PTEN-downmodu-
lated actin cytoskeletal organization (Fig. 9 A, P 1 Shc),
but the actin microfilament bundles tended to be shorter
than in control cells transfected with GFP tag only (Fig. 9
A, Ctr) with interrupted patterns of rhodamine-phalloidin
staining. These Shc-transfected cells showed increased
numbers of focal adhesions (Fig. 9 B, P 1 Shc), but not to
the extent seen in control cells (Fig. 9 B, Ctr). Activated
MEK1 produced similar patterns of partially enhanced ac-
tin microfilament organization (Fig. 9 A, P 1 Mek) that
were not organized to the level of control cells. As re-
ported above, both transfectants showed enhanced ran-
dom motility.
In contrast, FAK-cotransfected cells showed relatively
complete restoration of extensive and oriented patterns of
actin microfilament bundles (Fig. 9 A, P 1 FAK) with ex-
tensive focal adhesions (Fig. 9 B, P 1 FAK) as detected by
antipaxillin staining. Cells transfected with p130Cas, which
also showed enhanced directional migration, also showed
strongly organized actin cytoskeleton (Fig. 9 A, P 1 Cas)
as well as well organized focal contacts (Fig. 9 B, P 1 Cas).
These results establish distinct effects of Shc and FAK
pathways on the actin cytoskeleton and focal adhesions,
both of which are downmodulated by PTEN.
To quantify these apparent differences in morphological
effects of signaling by FAK and Shc pathways, we applied
a semi-quantitative morphometric measure for actin mi-
Figure 9. Differential effects
of Shc and FAK pathways on
enhancing actin cytoskeletal
organization and focal con-
tact formation downmodu-
lated by PTEN. U-87MG
cells were transfected with
various constructs and se-
lected as described above.
They were allowed to spread
on fibronectin-coated cover-
slips overnight in complete
culture medium, and then
stained with rhodamine-
phalloidin to detect F-actin
(A) and with antipaxillin an-
tibody to detect focal con-
tacts (B). Ctr, cells trans-
fected with GFP (2) only; P,
cells transfected with GFP-
PTEN only; in the other
frames, cells were cotrans-
fected with GFP-PTEN plus
each of the indicated plas-
mids; Mek, constitutively ac-
tivated MEK1; and Cas,
p130Cas. Bar, 20 mm.The Journal of Cell Biology, Volume 146, 1999 400
crofilament orientation that involves sampling and scoring
a site within each quadrant of the cell for local actin fila-
ment orientation (see Materials and Methods). This actin
orientation index confirmed the restoration of a striking
degree of actin microfilament orientation in FAK- or
p130Cas-overexpressing PTEN transfectant cells, as op-
posed to the relatively random organization of short actin
filaments in Shc- and activated MEK1-overexpressing
cells (Fig. 10, left). We also counted total numbers of focal
adhesions in each cell and found that Shc and activated
MEK1 had a lesser but significant ability to rescue focal
adhesion formation downregulated by PTEN as compared
with FAK and p130Cas (Fig. 10, right).
Discussion
Cell migration is a complex process that can be regulated
by multiple mechanisms, including by the newly discov-
ered tumor suppressor protein PTEN (Tamura et al., 1998,
1999a). This phosphatase has both phosphoinositol lipid
and phosphoprotein substrates (Maehama and Dixon,
1998; Myers et al., 1998; Tamura et al., 1998). In this study,
we have explored the integration of the regulation of cell
migration by PTEN, Shc, and FAK pathways. We exam-
ined the intriguing possibility that the effects of PTEN on
Shc phosphorylation levels and on cell migration might be
causally related, e.g., through a previously undescribed
Shc-initiated pathway for regulation of the speed or direc-
tionality components of cell migration.
Using transfection reconstitution, dominant negative,
and biochemical approaches, we have found the following.
(a) We have established a mechanism for our previous ob-
servation that PTEN transfection reduces the tyrosine
phosphorylation of Shc and inhibits MAP kinase activa-
tion by demonstrating that PTEN can interact with Shc
and can directly dephosphorylate it in vitro; we also show
here that Shc overexpression can rescue PTEN-inhibited
MAP kinase activation in U-87MG cells. (b) We have
found that Shc overexpression can stimulate integrin-
mediated cell migration and spreading downregulated by
PTEN. (c) Conversely, we have demonstrated that cell mi-
gration is inhibited by a dominant negative mutant of Shc
partially mimicking the action of PTEN. We also estab-
lished that PTEN, Shc, and FAK regulate cell movement
through two different mechanisms: one is a pathway from
Shc through the MAP kinase pathway leading to the stim-
ulation of random cell motility, and the other is from FAK
through p130Cas leading to stimulation of directionally per-
sistent cell migration. (e) We also have demonstrated that
inhibition of the Shc component of migration results in
slower but more directionally persistent migration because
of retention of the FAK component of migration. (f) We
have established that the increased random motility ac-
companying Shc and activated MEK1 action is associated
with only partial cytoskeletal and focal contact enhance-
ment, whereas the directional migration induced by FAK
and p130Cas correlates with more extensive, oriented actin
microfilament bundle (stress fiber) organization and focal
contact formation. (g) Finally, we have demonstrated that
the Shc/MEK1 pathway can enhance MAP kinase acti-
vation without affecting FAK/p130Cas phosphorylation,
whereas moderate overexpression of FAK restores levels
of tyrosine-phosphorylated FAK and p130Cas and stimu-
lates migration with minimal effects on MAP kinase acti-
vation. These studies define two distinct pathways for reg-
ulating speed and directionality of cell migration that
counterbalance and interdigitate with actions of the PTEN
tumor suppressor protein.
The adapter protein Shc has been linked to specific in-
tegrin-dependent signaling pathways (Wary et al., 1996,
1998). Overexpression of Shc also reportedly enhances cell
migration and growth in response to hepatocyte growth
factor (Pelicci et al., 1995). Our studies provide, to our
knowledge, the first report that Shc upregulates random
cell migration mediated by integrins and serum factors in a
process that opposes its downregulation by PTEN. Sup-
porting this concept, overexpression of a dominant nega-
tive form of Shc, doubly mutated by changing tyrosines
239 and 317 to phenylalanine, substantially inhibits the
random component of cell motility on fibronectin. A puta-
tive integrin-specific mutant in which only tyrosine 317
was mutated suggested that the ratio of integrin versus
growth factor contribution to migration was roughly 40:60%.
We previously reported that PTEN inhibits integrin-
mediated MAP kinase activation in this glioma cell line and
find in this study that overexpression of Shc can rescue in-
tegrin-stimulated MAP kinase activation. Moreover, we
find that transfection of constitutively activated MEK1 to
activate MAP kinase can mimic the effects of Shc on ran-
dom cell movement on fibronectin. In addition, the MEK
inhibitor PD98059 substantially inhibits Shc-stimulated
Figure 10. Quantitative analysis of effects of Shc and FAK sig-
naling pathways on actin cytoskeletal organization and focal ad-
hesions downregulated by PTEN. Cells were transfected with
various plasmids and stained as described in Fig. 9. (Left) Actin
orientation was analyzed by F-actin staining and quantified using
four fields per cell as described in Materials and Methods. The
actin orientation index represents the mean number of sampling
boxes that were positive for actin orientation per cell. (Right) Fo-
cal adhesion plaques were stained by antipaxillin antibody and
the number of focal adhesions was counted for each cell. Error
bars indicate SD of results from at least 15 cells. Asterisk, P ,
0.0001 versus transfection by GFP-PTEN alone or GFP (2)
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migration but does not inhibit FAK-stimulated migration.
These findings suggest that Shc and PTEN can regulate
cell motility by activation or suppression of the MAP ki-
nase pathway. In fact, MAP kinase activation can acceler-
ate integrin-mediated cell motility in some cells (Leaves-
ley et al., 1993; Yenush et al., 1994; Klemke et al., 1997;
Rigot et al., 1998), though not in others (Bornfeldt et al.,
1994; Coffer et al., 1998). A recent study has shown that
activated MAP kinase can directly phosphorylate and acti-
vate myosin light chain kinase, leading to phosphorylation
of myosin light chains and promoting the cytoskeletal con-
traction necessary for cell movement (Klemke et al.,
1997). Interestingly, EGF has been reported recently to
stimulate random cell migration (Ware et al., 1998), which
we speculate may also be related to its well-known en-
hancement of MAP kinase activation.
FAK also appears to have important roles in integrin
signaling and cell migration. In CHO cells, FAK promotes
integrin-mediated cell migration through the activation of
p130Cas (Cary et al., 1998). Overexpression of FAK or
p130Cas can also effectively rescue cell migration inhibited
by PTEN (Tamura et al., 1999a and in this study). For
comparing the roles of Shc versus FAK on cell motility, we
used time-lapse video microscopy to examine rates and
paths of cell motility, rather than only evaluating final out-
comes using the Boyden chamber or in vitro scratch
wound-healing assays. Our studies establish that Shc and
downstream-activated MAP kinase (ERK) upregulate
random cell motility. In clear contrast, FAK or down-
stream p130Cas upregulates directional motility. FAK may
regulate migration using a pathway dependent on phos-
phatidylinositol 39-kinase, e.g., as suggested by experi-
ments using Wortmannin (this paper and Reiske et al.,
1999). However, determining the mechanisms of phos-
phatidylinositol 39-kinase involvement will require exten-
sive future analysis. As summarized above, biochemical
analyses in this cell line of the specificity (a) of Shc versus
FAK for activation of MAP kinase, (b) of FAK but not
Shc specificity for stimulating phosphorylation of FAK
and p130Cas, and (c) of Shc but not FAK specificity for
stimulation of Shc phosphorylation, also underscore the
existence of distinct mechanisms. Taken together, our
transfection and biochemical studies strongly suggest that
there are at least two separate pathways for regulation of
the velocity and directionality components of cell motility,
and these pathways appear to be additive (Fig. 11).
FAK provides one of several possible pathways for
activation of the Ras–MAP kinase signaling pathway
(Schlaepfer et al., 1994). However, in contrast to results
with 293 and 3T3 cells, FAK does not appear to have
strong effects on this pathway in U-87MG cells (data in
this paper and Gu, J., unpublished results). In contrast to
FAK, Shc is the more plausible effector for integrin- and
growth factor–mediated MAP kinase activation in these
cells since dominant negative Shc overexpression can ef-
fectively inhibit MAP kinase activation (data not shown).
Cell migration can be viewed as a process regulated by
counterbalanced signals that can control rates of motility
by several mechanisms. Strength of cell adhesion is one
mechanism, where suboptimal, optimal, or inhibitory de-
grees of cell adhesion can regulate speed of locomotion
(Duband et al., 1991; Schmidt et al., 1993; Akasaka et al.,
1995; Gilmore and Romer, 1996; Huttenlocher et al., 1996;
Palecek et al., 1997). In fact, extensive formation of focal
adhesions has been linked to the slowing of cell migration
(Couchman and Rees, 1979; Duband et al., 1988; Dunlevy
and Couchman, 1993; Ilic et al., 1995). In addition, how-
ever, cytoskeletal systems are likely to play important
roles in modulating rates and directionality of migration
(Zigmond, 1993; Oliver et al., 1994; Huttenlocher et al.,
1995). The distinct pathways involving Shc–MAP kinase
versus FAK-p130Cas defined in this paper produce distinct
effects on the actin cytoskeleton and focal contact organi-
zation. Although both pathways produce cell spreading
and increased organization of the actin-containing cyto-
skeleton downregulated by PTEN, Shc and MEK1 induced
less actin organization compared with the more strongly
organized and oriented actin bundles characteristic of
FAK and p130Cas action. This enhanced orientation of the
cytoskeleton is consistent with the maintenance of direc-
tional migration, although other mechanisms cannot be
entirely excluded. It is noteworthy that this extent of focal
Figure 11. Model depicting proposed roles of PTEN, Shc, and
FAK in integrin- and growth factor–mediated cell motility.
Integrin and growth factors can collaboratively or separately
stimulate the Shc-MAP kinase pathway. Integrin receptor en-
gagement with fibronectin stimulates both FAK and Shc phos-
phorylation, and each initiates a distinct downstream signaling
pathway activating either persistent movement or random mi-
gration; these pathways are additive. PTEN inhibits integrin-
mediated FAK and Shc phosphorylation by direct dephosphor-
ylation, thereby inhibiting cell migration and spreading. This
model depicts at least two pathways for downstream regulation
of cell migration in U-87MG cells: one involving Shc to a MAP
kinase pathway producing random motility and the other a
FAK to p130Cas pathway involving directional migration. For
activation of the Shc random motility pathway, the contribu-
tions of integrins compared with serum growth factors were es-
timated to be roughly 40 versus 60% in these cells, as deter-
mined by a putative integrin-specific Shc mutant. It should also
be noted, however, that higher levels of FAK overexpression
can activate FAK and affect the Shc pathway in 293 cells as described (Schlaepfer and Hunter, 1997, and this study; dashed lines). Sum-
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contact formation and actin organization was obviously
not sufficiently high to retard cell migration, which was ac-
celerated. Taken together, these results suggest that an in-
termediate level of focal adhesion formation and actin
microfilament organization are optimal for the highest ve-
locity and directionality of migration of these cells and
that speed and directionality of migration are separable.
Besides the phosphoproteins examined in this study,
PTEN has a major lipid substrate that is important biolog-
ically. PTEN directly dephosphorylates PIP3, which is pro-
duced by phosphatidylinositol 39-kinase and can activate
the PKB/Akt signaling pathway. PTEN is thought to regu-
late cell growth and cell death by apoptosis and/or anoikis
via this pathway (Davies et al., 1998; Haas-Kogan et al., 1998;
Li et al., 1998; Myers et al., 1998; Stambolic et al., 1998; Su-
zuki et al., 1998; Tamura et al., 1999b; Wu et al., 1998).
Nevertheless, the intertwined regulatory effects of Shc,
PTEN, and FAK on migration that we describe do not ap-
pear to involve this PKB/Akt pathway. Even though phos-
phatidylinositol 39-kinase is known to have regulatory ef-
fects on cell migration (Keely, et al., 1997; Shaw et al.,
1997; Sander et al., 1998), recent studies indicate that
phosphatidylinositol 39-kinase induction of scattering acts
through effectors other than PKB/Akt and requires at
least basal MAP kinase function (Khwaja et al., 1998). In
this study, inhibition of phosphatidylinositol 39-kinase by
Wortmannin also reduced the rate of cell migration of
U-87MG cells, but it targeted the FAK pathway selec-
tively. We have been unable to find any reports of PKB/
Akt regulation of cell movement. In fact, we found that
dominant negative Akt did not affect U-87MG cell move-
ment on fibronectin, suggesting no role for PKB/Akt in
regulating migration, at least in this cell system.
In conclusion, we propose that there are at least three
signaling pathways regulated by PTEN: (1) a PIP3–PKB/
Akt pathway affecting growth and apoptosis, (2) a Shc–
MAP kinase pathway affecting random cell motility, and
(3) a FAK-p130Cas pathway that contributes a directional
motility component to cell migration. FAK and p130Cas
have been related to effects of PTEN on regulating tumor
cell invasiveness (Tamura et al., 1999a) and this study sug-
gests that their effects were likely due to the directional
component of migration. These different regulatory sys-
tems appear to be intertwined and provide countervailing
influences on speed and directionality of integrin-medi-
ated cell migration. Integration of their actions provides a
mechanism for intracellular regulation of cell migration.
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